The following is a summary of the study, “Longitudinal evaluation of individuals with severe alpha-1 antitrypsin deficiency ...

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Target ALS, a leading organization dedicated to breaking down barriers to accelerate amyotrophic lateral sclerosis (ALS) ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

In severe asthma, lower wall thickness on CT scans and increased FeNO may indicate increased airway inflammation linked to lung function decline.

An upcoming clinical trial will test whether empagliflozin might be able to improve heart health in pulmonary arterial ...

Despite gathering over 100 public comments that criticized the multi-million dollar settlement between the Department of Justice and Norfolk Southern to remedy the impacts of last year’s train ...

Despite gathering over 100 public comments that criticized the multi-million dollar settlement between the Department of Justice and Norfolk Southern to remedy the impacts of last year’s train ...

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.

Columnist Charlene Marshall was confused when her latest pulmonary function test results didn't seem to reflect how she was feeling.